Form 4: Mardi Dier Sells MDGL Shares for Tax Obligations
Insider Transaction Report
Mardi Dier, EVP and CFO of Madrigal Pharmaceuticals, sold 1,183 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
Summary
- Mardi Dier, Executive Vice President and Chief Financial Officer of Madrigal Pharmaceuticals, Inc. (MDGL), reported a sale of common stock.
- The transaction involved the disposition of 1,183 shares of common stock on March 2, 2026.
- The shares were sold at a price of $427.21 per share.
- This sale was automatic and non-discretionary, executed by the Issuer on behalf of Ms. Dier to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following this transaction, Ms. Dier directly beneficially owns 9,257 shares of Madrigal Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. It is a routine, non-discretionary transaction for tax purposes related to executive compensation and does not reflect a change in the executive's or company's outlook.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine occurrence in the biotechnology and pharmaceutical industries. These transactions are typically non-discretionary and often pre-arranged under Rule 10b5-1 plans, indicating an administrative event rather than a change in investment sentiment.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in the executive's confidence or the company's fundamentals.
- Employees: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 03/02/2026 | Date of transaction where 1,183 shares of common stock were sold. |
Keywords
Madrigal Pharmaceuticals, MDGL, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.